The Laser and Skin Surgery Center of Indiana, Carmel, Indiana 46032, USA.
Dermatol Ther. 2011 Jan-Feb;24(1):82-93. doi: 10.1111/j.1529-8019.2010.01381.x.
With an incidence of over 3.5 million nonmelanoma skin cancers (NMSCs) per year in the United States, there is an increasing need for effective, cost-effective treatments for NMSC. When surgical excision is impractical or not feasible, methyl aminolevulinate photodynamic therapy (MAL-PDT) has demonstrated consistently high long-term cure rates ranging from 70-90%, with superior cosmetic outcomes compared with other treatment modalities. With the exception of invasive squamous cell carcinoma, MAL-PDT has been successful in treating all types of NMSC, especially in patients with multiple comorbidities, field cancerization, and lesions in cosmetically sensitive locations. Herein, a step-by-step description of the procedure for MAL-PDT is provided, followed by a review of outcomes from large clinical trials performed over the past 15 years for each variant of NMSC. After reading this review, clinicians should have a thorough understanding of the benefits and limits of MAL-PDT, and should be able to add this valuable procedure to their armamentarium of therapies for NMSC.
在美国，每年有超过 350 万例非黑素瘤皮肤癌（NMSC），因此对于 NMSC 而言，人们对于有效且具有成本效益的治疗方法的需求日益增加。当手术切除不切实际或不可行时，甲基氨基酮戊酸光动力疗法（MAL-PDT）已证明具有始终保持较高的长期治愈率（70-90%），与其他治疗方式相比，具有更好的美容效果。除侵袭性鳞状细胞癌外，MAL-PDT 已成功治疗所有类型的 NMSC，尤其是患有多种合并症、区域性癌变和美容敏感部位病变的患者。本文提供了 MAL-PDT 程序的分步说明，并回顾了过去 15 年中针对每种 NMSC 变体进行的大型临床试验的结果。阅读完这篇综述后，临床医生应该对 MAL-PDT 的益处和局限性有全面的了解，并能够将这种有价值的治疗方法添加到他们的 NMSC 治疗方案中。
